ABEO · Abeona Therapeutics Inc

-

Please sign in to comment on ABEO

1 Comment

Admin

4 years, 1 month ago

Abeona Therapeutics Inc is currently in a long term downtrend where the price is trading 13.0% below its 200 day moving average.

From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.1.

Abeona Therapeutics Inc's total revenue rose by inf% to $3M since the same quarter in the previous year.

Its net income has increased by 3.7% to $-16M since the same quarter in the previous year.

Finally, its free cash flow grew by 88.6% to $-2M since the same quarter in the previous year.

Based on the above factors, Abeona Therapeutics Inc gets an overall score of 4/5.

Exchange	NASDAQ
CurrencyCode	USD
Industry	Biotechnology
ISIN	US00289Y1073
Sector	Healthcare

Market Cap	257M
PE Ratio	None
Target Price	19.7143
Beta	1.68
Dividend Yield	None

ABOUT

Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

ABEO · Abeona Therapeutics Inc

-

Abeona Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Abeona Therapeutics Inc using a moving average strategy